Renaissance Technologies’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Renaissance Technologies’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-116,562	Closed	-$2.7M	–	4390
2023 Q1	$2.7M	Sell	116,562 -65,100	-36%	-$1.55M	﹤0.01%	1839
2022 Q4	$4.76M	Sell	181,662 -37,680	-17%	-$835K	0.01%	1554
2022 Q3	$4.31M	Sell	219,342 -53,620	-20%	-$1.08M	0.01%	1526
2022 Q2	$4.77M	Buy	272,962 +6,220	+2%	+$97.6K	0.01%	1598
2022 Q1	$4.36M	Sell	266,742 -101,900	-28%	-$1.39M	0.01%	1698
2021 Q4	$6.01M	Sell	368,642 -162,920	-31%	-$2.32M	0.01%	1402
2021 Q3	$6.78M	Sell	531,562 -113,580	-18%	-$1.49M	0.01%	1274
2021 Q2	$9.11M	Sell	645,142 -96,700	-13%	-$1.55M	0.01%	1240
2021 Q1	$11.5M	Sell	741,842 -94,244	-11%	-$1.54M	0.01%	1098
2020 Q4	$13.3M	Sell	836,086 -40,716	-5%	-$614K	0.01%	981
2020 Q3	$10.7M	Sell	876,802 -52,060	-6%	-$698K	0.01%	1084
2020 Q2	$10.7M	Buy	928,862 +18,900	+2%	+$261K	0.01%	1174
2020 Q1	$12.5M	Sell	909,962 -17,700	-2%	-$209K	0.01%	1024
2019 Q4	$5.47M	Buy	927,662 +380,022	+69%	+$2.07M	﹤0.01%	1794
2019 Q3	$2.9M	Buy	547,640 +185,200	+51%	+$1.23M	﹤0.01%	2074
2019 Q2	$2.79M	Buy	362,440 +130,720	+56%	+$1.99M	﹤0.01%	2158
2019 Q1	$4.61M	Buy	231,720 +158,720	+217%	+$2.77M	﹤0.01%	1857
2018 Q4	$964K	Buy	+73,000	New	+$1.46M	﹤0.01%	2590
2018 Q3	–	Sell	-11,800	Closed	-$413K	–	3624
2018 Q2	$413K	Sell	11,800 -35,660	-75%	-$1.37M	﹤0.01%	2888
2018 Q1	$2.21M	Sell	47,460 -15,300	-24%	-$560K	﹤0.01%	2276
2017 Q4	$2.35M	Sell	62,760 -23,420	-27%	-$1.02M	﹤0.01%	2253
2017 Q3	$4.59M	Buy	86,180 +35,440	+70%	+$2.11M	0.01%	1829
2017 Q2	$2.89M	Buy	50,740 +14,360	+39%	+$721K	﹤0.01%	2052
2017 Q1	$1.96M	Buy	36,380 +32,160	+762%	+$1.82M	﹤0.01%	2252
2016 Q4	$241K	Buy	+4,220	New	+$255K	﹤0.01%	2950
2016 Q1	–	Sell	-6,920	Closed	-$974K	–	3581
2015 Q4	$974K	Buy	+6,920	New	+$940K	﹤0.01%	2472

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies's KDNY Position: Q2 2023 in Review

Renaissance Technologies sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 116,562 shares — an estimated $2.7M sold.

Renaissance Technologies first reported a position in KDNY in Q4 2015 and held it in 26 quarters. The position peaked at $13.3M in Q4 2020. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Renaissance Technologies reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 116,562 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.7M.
Renaissance Technologies first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 26 quarters.
Renaissance Technologies's Chinook Therapeutics, Inc. Common Stock position peaked at $13.3M in Q4 2020.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.